Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines.
Serum-free supernatants from in vitro maintained gastrointestinal cancer and melanoma cell lines inhibit the generation of lymphokine (IL-2) activated killer (LAK) cells in a time and dose-related manner. Concentrations as low as 5% can inhibit the generation of LAK cytotoxicity but inhibition of proliferation is not observed until higher concentrations are included in the culture system. Inhibition is not observed with supernatants from a breast cancer cell line nor with supernatants from normal cells. There was complete concordance between the capacity of the tumour cells themselves to inhibit LAK generation and the presence of inhibitory activity in the corresponding supernatant. The inhibitory factor(s) is stable after heating to 44 and 56 degrees C. Production of the inhibitory factor(s) is sensitive to metabolic inhibitors and has a molecular weight greater than 25 kD. The inhibition of LAK cell stimulation by tumour cells may partially explain the failure of adoptively transferred LAK cells and IL-2 therapy to cause tumour regression in man.
Guillou
P J
PJ
University Department of Surgery, St James's University Hospital, Leeds, UK.
Ramsden
C W
CW
Somers
S S
SS
Sedman
P C
PC
D002460:Cell Line; D006801:Humans; D007376:Interleukin-2 / Q000502:physiology*; D007694:Killer Cells, Natural / Q000187:drug effects*; D008213:Lymphocyte Activation / Q000187:drug effects; D013491:Suppressor Factors, Immunologic / Q000502:physiology*; D014407:Tumor Cells, Cultured / Q000378:metabolism*
D007376:Interleukin-2; D013491:Suppressor Factors, Immunologic